Janssen-Cilag International gets European Commission nod for subcutaneous Rybrevant for advanced EGFR-mutated non-small cell lung cancer Ruchika Sharma8 April 2025 11:30 AM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) for an extension...
European Commission approves Janssen-Cilag International Rybrevant, Lazcluze combo for first-line treatment of lung cancer Ruchika Sharma31 Dec 2024 11:30 AM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has approved a Type II...
JnJ chemotherapy free lung cancer treatment Rybrevant plus Lazcluze gets USFDA okay Ruchika Sharma21 Aug 2024 12:30 PM ISTNew Jersey: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) plus...
CDSCO Panel Approves J&J's Protocol Amendment Proposal For Amivantamab, Lazertinib combination Dr. Divya Colin14 April 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO Panel grants J&J Protocol Amendment proposal to study anticancer drug Amivantamab and Lazertinib Dr. Divya Colin9 Jan 2024 5:45 PM ISTNew Delhi: Regarding the study of Amivantamab and Lazertinib in combination with platinum-based chemotherapy compared with platinum-based chemotherapy...
Janssen seeks EMA marketing nod for Lazertinib plus Rybrevant for EGFR-Mutated Non Small Cell Lung Cancer Ruchika Sharma25 Dec 2023 3:30 PM ISTBelgium: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a marketing authorisation application...
JnJ seeks USFDA nod for Rybrevant plus Lazertinib for EGFR-Mutated Non-Small Cell Lung Cancer Ruchika Sharma24 Dec 2023 12:30 PM ISTRaritan: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Phase 3 Mariposa study evaluating Rybrevant plus Lazertinib meets primary endpoint in PFS in Non-Small Cell Lung Cancer: Janssen Ruchika Sharma2 Oct 2023 10:00 AM ISTRartan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the Phase 3 MARIPOSA study...
Janssen declares positive topline results from Phase 3 study evaluating RYBREVANT given with, without lazertinib combined with chemotherapy versus chemotherapy alone Ruchika Sharma9 Sept 2023 1:45 PM ISTNew Jersey: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the three-arm Phase 3 ...
Johnson & Johnson Gets CDSCO Panel Okay To Study Anti-cancer Drug Lazertinib/Amivantamab Dr. Divya Colin4 Nov 2022 6:00 PM ISTNew Delhi: Pharmaceutical major Johnson and Johnson has got green signal from the Subject Expert Committee (SEC) functional under the Central Drug...
